Browse MYH11

Summary
SymbolMYH11
Namemyosin, heavy chain 11, smooth muscle
Aliases SMMHC; SMHC; myosin, heavy polypeptide 11, smooth muscle; AAT4; FAA4; myosin heavy chain 11; myosin heavy ch ......
Chromosomal Location16p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Melanosome Note=Identified by mass spectrometry in melanosome fractions from stage I to stage IV. Thick filaments of the myofibrils.
Domain PF00063 Myosin head (motor domain)
PF02736 Myosin N-terminal SH3-like domain
PF01576 Myosin tail
Function

Muscle contraction.

> Gene Ontology
 
Biological Process GO:0003012 muscle system process
GO:0006936 muscle contraction
GO:0006939 smooth muscle contraction
GO:0007507 heart development
GO:0010927 cellular component assembly involved in morphogenesis
GO:0014706 striated muscle tissue development
GO:0014866 skeletal myofibril assembly
GO:0030198 extracellular matrix organization
GO:0030239 myofibril assembly
GO:0030241 skeletal muscle myosin thick filament assembly
GO:0031032 actomyosin structure organization
GO:0031033 myosin filament organization
GO:0031034 myosin filament assembly
GO:0035051 cardiocyte differentiation
GO:0042692 muscle cell differentiation
GO:0043062 extracellular structure organization
GO:0048251 elastic fiber assembly
GO:0048738 cardiac muscle tissue development
GO:0048739 cardiac muscle fiber development
GO:0048747 muscle fiber development
GO:0051146 striated muscle cell differentiation
GO:0055001 muscle cell development
GO:0055002 striated muscle cell development
GO:0055006 cardiac cell development
GO:0055007 cardiac muscle cell differentiation
GO:0055013 cardiac muscle cell development
GO:0060537 muscle tissue development
GO:0071688 striated muscle myosin thick filament assembly
GO:0085029 extracellular matrix assembly
Molecular Function GO:0003774 motor activity
GO:0003779 actin binding
GO:0005516 calmodulin binding
GO:0008307 structural constituent of muscle
GO:0051015 actin filament binding
Cellular Component GO:0005859 muscle myosin complex
GO:0015629 actin cytoskeleton
GO:0016459 myosin complex
GO:0016460 myosin II complex
GO:0032982 myosin filament
GO:0042470 melanosome
GO:0043292 contractile fiber
GO:0044449 contractile fiber part
GO:0048770 pigment granule
> KEGG and Reactome Pathway
 
KEGG hsa04270 Vascular smooth muscle contraction
hsa04530 Tight junction
Reactome R-HSA-422475: Axon guidance
R-HSA-1266738: Developmental Biology
R-HSA-2682334: EPH-Ephrin signaling
R-HSA-3928663: EPHA-mediated growth cone collapse
R-HSA-397014: Muscle contraction
R-HSA-195258: RHO GTPase Effectors
R-HSA-5627117: RHO GTPases Activate ROCKs
R-HSA-5625900: RHO GTPases activate CIT
R-HSA-5627123: RHO GTPases activate PAKs
R-HSA-5625740: RHO GTPases activate PKNs
R-HSA-400685: Sema4D in semaphorin signaling
R-HSA-416572: Sema4D induced cell migration and growth-cone collapse
R-HSA-373755: Semaphorin interactions
R-HSA-162582: Signal Transduction
R-HSA-194315: Signaling by Rho GTPases
R-HSA-445355: Smooth Muscle Contraction
Summary
SymbolMYH11
Namemyosin, heavy chain 11, smooth muscle
Aliases SMMHC; SMHC; myosin, heavy polypeptide 11, smooth muscle; AAT4; FAA4; myosin heavy chain 11; myosin heavy ch ......
Chromosomal Location16p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MYH11 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolMYH11
Namemyosin, heavy chain 11, smooth muscle
Aliases SMMHC; SMHC; myosin, heavy polypeptide 11, smooth muscle; AAT4; FAA4; myosin heavy chain 11; myosin heavy ch ......
Chromosomal Location16p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MYH11 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMYH11
Namemyosin, heavy chain 11, smooth muscle
Aliases SMMHC; SMHC; myosin, heavy polypeptide 11, smooth muscle; AAT4; FAA4; myosin heavy chain 11; myosin heavy ch ......
Chromosomal Location16p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MYH11 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.5440.257
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.6020.54
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4880.48
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.6890.546
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.350.93
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.120.822
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.6130.232
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.0430.402
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1560.909
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2980.831
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.2810.481
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.6180.0387
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MYH11 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.15.91.21
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1031033.3-23.30.423
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277322.26.815.40.0644
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275922.28.513.70.0918
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.35.98.40.613
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.49.16.31
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.2022.20.12
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.93.74.20.636
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.6013.60.279
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMYH11
Namemyosin, heavy chain 11, smooth muscle
Aliases SMMHC; SMHC; myosin, heavy polypeptide 11, smooth muscle; AAT4; FAA4; myosin heavy chain 11; myosin heavy ch ......
Chromosomal Location16p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MYH11. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMYH11
Namemyosin, heavy chain 11, smooth muscle
Aliases SMMHC; SMHC; myosin, heavy polypeptide 11, smooth muscle; AAT4; FAA4; myosin heavy chain 11; myosin heavy ch ......
Chromosomal Location16p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MYH11. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MYH11.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMYH11
Namemyosin, heavy chain 11, smooth muscle
Aliases SMMHC; SMHC; myosin, heavy polypeptide 11, smooth muscle; AAT4; FAA4; myosin heavy chain 11; myosin heavy ch ......
Chromosomal Location16p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MYH11. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMYH11
Namemyosin, heavy chain 11, smooth muscle
Aliases SMMHC; SMHC; myosin, heavy polypeptide 11, smooth muscle; AAT4; FAA4; myosin heavy chain 11; myosin heavy ch ......
Chromosomal Location16p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MYH11 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMYH11
Namemyosin, heavy chain 11, smooth muscle
Aliases SMMHC; SMHC; myosin, heavy polypeptide 11, smooth muscle; AAT4; FAA4; myosin heavy chain 11; myosin heavy ch ......
Chromosomal Location16p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MYH11 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMYH11
Namemyosin, heavy chain 11, smooth muscle
Aliases SMMHC; SMHC; myosin, heavy polypeptide 11, smooth muscle; AAT4; FAA4; myosin heavy chain 11; myosin heavy ch ......
Chromosomal Location16p13.11
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MYH11 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting MYH11.
ID Name Drug Type Targets #Targets
DB04444Tetrafluoroaluminate IonSmall MoleculeATP2A1, CMPK1, GNAI1, GNAT1, MYH11, MYH146